The Practising Pharmacists Association of Hong Kong

DH Update 21/02/2012

Mon, 20 Feb 2012 06:50:00 +1600

European Medicines Agency: New Contraindications and Warnings for Aliskire-containing products

Avastin(bevacizumab): Counterfeit Product - FDA Issues Letters to 19 Medical Practices

PPAHK

Re: PPA Townhall Meeting on Pharmacists Manpower Planning

Mon, 20 Feb 2012 06:50:00 +1600

Re: PPA Townhall Meeting on Pharmacists Manpower Planning

On behalf of the PPAHK, please kindly be invited to a Townhall Meeting to discuss one of the most

important current issues of our profession - Pharmacists Manpower Planning.

As the PPA has been invited to be one of the committee members to represent our members' views on the

Strategic Manpower Planning of Pharmacists by the government, we would like to hear your views at the

coming Townhall meeting to be held on:

Date: 5th March 2012

Time: 7:00pm-8:00pm

Venue: Room 704, Boys' & Girls' Clubs Association of Hong Kong, 3 Lockhart Road, Wanchai, Hong Kong

Please kindly return the completed Reply Form to 3003 0112 to reserve your seat.

Looking forward to seeing you at the Town Hall Meeting event.

Yours faithfully,

Iris Chang

President

REPLY FORM

Alert on PegIntron Redipen Single-dose delivery system from DH

Sun, 26 Sep 2010 20:20:00 +1600

Please find the press release from the Department of Health regarding a alert for your follow-up action.

Yours faithfully,

Iris Chang

President

PPAHK

Pharmacovigilance Alert- Guidelines for Pharmacists on Sibutramine

Fri, 29 Jan 2010 15:52:43 +1600

Further to the reports from the FDA, MHRA and EMA on the increased risk of heart attack and stroke in patients with history of CV diseases when using sibutramine, pharmacists are reminded that the following contra-indications should be excluded from your patient groups when dispensing sibutramine.

1. History of coronary artery disease (heart attack and angina)

2. History of stroke or transient ischemic attack (TIA)

3. History of heart arrhythmias

4. History of congestive heart failure

5. History of peripheral arterial disease

6. Uncontrolled hypertension (e.g. > 145/90mmHg)

Pharmacist should highlight the potential serious ADR with their patients, and if possible, pharmacists should check with the physicians issuing the prescription for review.

Should patients complain of any adverse drug reaction from using sibutramine, please promptly report to PPA via 6888 8250 and/or directly to the Dept of Health.

Thank you very much for your kind support for our efforts in pharmacovigilance and risk management for protecting the health of our patients.

link for FDA
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm

link for MHRA

http://www.mhra.gov.uk/NewsCentre/CON068470?dm_i=EQ,39RR,1SAKM,A77F,1

Yours faithfully,

Iris Chang
President, PPAHK